The University of Kansas Cancer Center

https://www.kucancercenter.org/

 

The University of Kansas Cancer Center
A

Phase II DREAMM-2: Belantamab Mafodotin in R/R MM

By The University of Kansas Cancer Center FEATURING Al-Ola Abdallah
By The University of Kansas Cancer Center FEATURING Al-Ola Abdallah
0 views
July 23, 2021
Comments 0
Login to view comments. Click here to Login

Featured Video

16:51
Incyte

Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk

Feat. C. Harrison

Featured Video

24:35
Indy Hematology Review

Current Approaches in the Treatment of Myeloproliferative Neoplasms

Feat. A. Tefferi
Videos
13:17
Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: Golcadomide, an Oral CELMoD, + R-CHOP in Patients…

Feat. M. Hoffmann
12:21
Insights from 2023 SABCS

SABCS 2023 Insights: "How to Treat TNBC"

Feat. P. Sharma
09:24
The University of Kansas Cancer Center

Treatment Sequence in mTNBC

Feat. P. Sharma
07:47
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "The X-7/7 Randomized Trial - Fixed Dose C…

Feat. C. Bohnenkamp
14:05
The University of Kansas Cancer Center

Five-Year Updates on Venetoclax + Obinutuzumab for Previously Untrea…

Feat. M. Hoffmann
13:40
SABCS 2021 Conference Coverage on VuMedi

Optimizing Use of HER2 Therapies in MBC

Feat. P. Sharma
10:44
The University of Kansas Cancer Center

Phase II DREAMM-2: Belantamab Mafodotin in R/R MM

Feat. A. Abdallah
07:59
The University of Kansas Cancer Center

2021 ASCO Updates From LIMBER-313 on Myelofibrosis: Parsaclisib + Ru…

Feat. A. Yacoub
08:58
The University of Kansas Cancer Center

ASCO 2021 Update on mTNBC: Considering Outcomes With Romidepsin / Ci…

Feat. P. Sharma
11:45
The University of Kansas Cancer Center

2021 Updates on MF: Addition of Parsaclisib in Patients With Subopti…

Feat. A. Yacoub
06:08
The University of Kansas Cancer Center

2020 Update on PARPi/Chemo Option in mTNBC: How Effective Is the Add…

Feat. P. Sharma